Hyperion DeFi, Inc. (HYPD) Research

Operating from the United States, Hyperion DeFi, Inc. is a company undergoing a significant shift from its foundational work in ophthalmic drug-delivery, known as Optejet. Its current trajectory involves establishing itself as the inaugural U.S. firm on Nasdaq to hold a cryptocurrency treasury, predominantly denominated in HYPE tokens originating from the Hyperliquid blockchain. Furthermore, Hyperion DeFi oversees the "Kinetiq × Hyperion" validator, persists with its decentralized finance (DeFi) staking strategies, and continues to advance its Optejet UFD™ technology for ocular health.

Market snapshot

Symbol
HYPD
Price
$3.45
Day change
-2.27%
Market cap
$17.2M
P/E ratio
-1.11x
52-week range
2.491-17.18
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$7.75

Peer companies

  • BioXcel Therapeutics, Inc. (BTAI)
  • electroCore, Inc. (ECOR)
  • Jasper Therapeutics, Inc. (JSPR)
  • Modular Medical, Inc. (MODD)
  • Mural Oncology plc (MURA)
  • Myomo, Inc. (MYO)
  • NeuroOne Medical Technologies Corporation (NMTC)
  • P3 Health Partners Inc. (PIII)

Recent insider activity

  • Jung Hyunsu — P-Purchase (500 shares) on 2026-06-02
  • Jung Hyunsu — P-Purchase (500 shares) on 2026-06-02
  • Jung Hyunsu — P-Purchase (2000 shares) on 2026-06-01
  • Jung Hyunsu — P-Purchase (5000 shares) on 2026-06-01
  • Jung Hyunsu — F-InKind (40000 shares) on 2026-05-27

Open Hyperion DeFi, Inc. (HYPD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.